The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1763
September 14, 2026
View Complete Issue         Table of Contents 2019 
mFLUSIVA — An mRNA-Based Influenza Vaccine
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
mFLUSIVA — An mRNA-Based Influenza Vaccine
September 14, 2026 (Issue: 1763)
The FDA has licensed mFLUSIVA (Moderna), the first mRNA-based influenza vaccine in the US, for prevention of influenza in adults ≥50 years old. mFLUSIVA will be available for the 2026-2027 influenza season. Three mRNA COVID-19 vaccines...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: mFLUSIVA — An mRNA-Based Influenza Vaccine
Article code: 1763b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.